What wonderful news that payers may actually reimburse pharma for technologies that can demonstrate reduced costs to payers. What refreshing news. There is so much happening in the beyond-the-pill space to wrap drugs in value added services and many of these have been found to provide better patient outcomes and less physician and hospital visits. Pharma have been working with digital health companies for over 2 decades from the Lifescan and Novo Nordics partnership from the early 2000s to all the ones being done today. All efforts have been to assist patients achieve better outcomes and help them manage their condition so by linking these efforts to AI powered data integration and analytics, we can prove the results of these efforts are having a beneficial impact on patient outcomes and reduced cost to the health system. Well done payers. All that is needed is to collect and integrate the data coming in from these initiatives, connect the dots with the cost reduction to payers, prove the case and apply for reimbursement for all apps and digital health initiatives. If you need help, let me know.
Pharma companies are discovering that developing apps and digital health technologies is just like developing drugs--at least when it comes to persuading payers to cover them. Payers say they're willing to reimburse for digital health technologies, the health economics consultancy Xcenda found in a recent survey. But they need proof first. “Payers want to see the clinical effectiveness of these digital health technologies and they want to understand the cost effectiveness,” Xcenda President Tommy Bramley told FiercePharmaMarketing in an interview. That may be why many payers are evaluating technologies, but few of those surveyed are currently covering them. Digital health purveyors, including pharma, need to better demonstrate the clinical and economic value to payers, Bramley said.